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The primary analysis of time-to-event data typically
makes the censoring at random assumption, that is,
that—conditional on covariates in the model—the dis-
tribution of event times is the same, whether they are
observed or unobserved. In such cases, we need to
explore the robustness of inference to more pragmatic
assumptions about patients post-censoring in sensitivity
analyses. Reference-based multiple imputation, which
avoids analysts explicitly specifying the parameters of
the unobserved data distribution, has proved attrac-
tive to researchers. Building on results for longitudinal
continuous data, we show that inference using a Tobit
regression imputation model for reference-based sensi-
tivity analysis with right censored log normal data is
information anchored, meaning the proportion of infor-
mation lost due to missing data under the primary anal-
ysis is held constant across the sensitivity analyses. We
illustrate our theoretical results using simulation and a
clinical trial case study.
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1 INTRODUCTION
However carefully clinical trials are designed and planned, some outcome data are often miss-
ing. This occurs when a patient is lost to follow-up, which could be, for example, due to
noncompliance with the study protocol, or stopping an assigned treatment due to experiencing
adverse effects.
When the outcome of interest is the time to an event, patients censored at their last-known
time point can be considered as generating a type of missing data. The event occurs after they
were last seen. Any analysis must make inherently untestable assumptions about the distribution
of the time from the last observed visit to the event. Therefore, censored data cause unavoidable
ambiguity in the analysis. Since we never know the true event time for censored data, it is impor-
tant to be clear about the assumptions made about such data, and the subsequent impact of these
assumptions on the conclusions. If a contextually implausible assumption concerning censored
data is made, then the results from the analysis might lead to potentially misleading conclusions,
which can directly influence patient care (among others Sterne et al., 2009; White & Carlin, 2010;
Ibrahim, Chu, & Chen, 2012; Jakobsen, Gluud, & Winkel, 2017).
Therefore, in a trial setting the ideal is for the primary analysis to make the most contextu-
ally plausible assumptions about the censored data; the conclusion from the primary analysis is
then tested using sensitivity analysis which makes different, contextually plausible assumptions
concerning the censored data.
In practice, the primary analysis of time-to-event data most often makes the censoring at
random (CAR) assumption, that is, that—conditional on covariates in the analysis model—the
distribution of event times is the same, whether they are observed or unobserved. In a sensitiv-
ity analysis, postcensoring behavior will typically then assume data are censored not at random
(CNAR), also known as informative censoring.
If the results from the primary and sensitivity analysis are broadly consistent, we can conclude
that for the sensitivity analysis scenarios investigated, the outcome from the primary analysis is
robust to contextually plausible departures from the primary assumption concerning the miss-
ing data mechanism. If this is not the case, and the conclusions change following the sensitivity
analysis, then the investigators should report the conditions under which the conclusions may
change, along with the relative likeliness of these circumstances occurring. These steps provide
more confidence in the results, especially when regulators are considering new treatments for
approval. Both the European Medicines Agency (EMA) and U.S. Food and Drug Administration
have underlined the importance of performing sensitivity analyses in clinical trials (CHMP, 2010;
NRC, 2010), with the recent EMA ICH E9 (R1) addendum providing clarity in terms of both
definitions and example scenarios for such sensitivity analyses CHMP (2019).
Multiple imputation (MI) has become a popular method for such missing data analyses both
for the primary analysis and subsequent sensitivity analyses, since there is software enabling
accessible implementation (e.g., proc MI SAS, 2003, mi impute and mimix Cro, Morris, Kenward,
& Carpenter, 2016; StataCorp., 2013, mice and InformativeCensoring Ruau et al., 2016; van Buuren
& Groothuis-Oudshoorn, 2011).
MI involves forming a suitable imputation model based on the observed data. Typically, this
will take the form of a regression model, with asymptotically normally distributed parameter
estimates. Repeated draws from this conditional predictive distribution of the missing data are
made to create multiple completed datasets. Each completed dataset is then analyzed using
the substantive analysis model of interest to obtain multiple treatment estimates (Carpenter &
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Kenward, 2013, chapter 2). Treatment and variance estimates are then averaged across multiply
imputed data sets using Rubin’s MI combination rules; provided the imputations are proper (e.g.,
Rubin 1987), statistical inferences have good frequentist properties.
Reference-based multiple imputation (RBMI), an approach originally proposed by Little and
Yau (1996), has recently gained popularity as a sensitivity analysis approach due to its inherent
practicality. Missing data are imputed by reference to an appropriately chosen group, or groups of
patients from the observed data. For example, observed data from one arm of a clinical trial can be
re-used to impute all unobserved data in the trial under a particular assumption, where all unob-
served are expected to behave like the specified “reference” arm. Recent practical applications of
RBMI are numerous, with examples in the fields of psychotherapy, endocrinology, and paediatric
and geriatric care (e.g. Philipsen et al. (2015), Jans et al. (2015), Billings et al. (2018), Atri, Frölich,
Ballard, et al. (2018)).
Carpenter, Roger, and Kenward (2013) defined a number of approaches for RBMI sensi-
tivity analysis for longitudinal data with a continuous endpoint, and one of these, “Jump to
Reference,” has recently been extended to the time-to-event setting (Atkinson, Kenward, Clay-
ton, and Carpenter (2019)). In summary, Jump to Reference imputes unobserved data using
an imputation distribution that has parameters from the patient’s randomized arm up to their
last observed time point, with parameters from a specified reference arm for unobserved time
points.
With RBMI methods, the model used for imputing data and analyzing data is no longer the
same (i.e., uncongenial, Meng, 1994), and this has provoked a discussion on the operating charac-
teristics of Rubin’s variance estimate in this context (Hughes, Sterne, & Tilling, 2014; Kim, Zeng,
& Taylor, 2017; Liu & Peng, 2016; Robins & Wang, 2000; Tang, 2018). In addition, with RBMI
we can intuitively understand that since we reuse data, in the analysis we increase the homo-
geneity between the groups we are seeking to compare. If we are not careful, this dilution or
mixing effect between groups decreases the variability of the resulting treatment estimate. We
view this as undesirable, since this reduced variability may be seen as a “reward” for missing
data.
However, recently Cro, Carpenter, and Kenward (2019) proved that, at least for continuous
longitudinal data, RBMI is information anchored, meaning that the proportion of information
lost due to missing data is held constant across the primary and sensitivity analysis. Here, we are
using “information” in a rather specific sense, defined to be the inverse of the derived estimator
of the sampling variance.
Furthermore, in their recent paper Atkinson et al. showed that, counterintuitively, the empir-
ical variance decreases as the proportion of censored data increases (columns 7 and 8 of Table 1
of reference 2), whereas information anchoring was shown to hold for Rubin’s variance estima-
tor (albeit with simulated data). Building on this work, and that of Cro et al., in this article we
provide theoretical results showing that information anchoring also holds for a reference-based
sensitivity analysis with a Tobit imputation model assuming truncated normal data. We illustrate
the approach with right censored log normal survival times, where the estimate is the difference
in mean survival times by treatment.
The remainder of the paper is organized as follows. The next section introduces our example
clinical trial dataset which will be used to illustrate the theoretical results. Section 3 defines
information anchoring in more detail. Section 4 presents the theoretical results, which are then
compared with simulated data in Section 5, along with an illustration of the approach based on
the clinical trial data in Section 6. We finish with a discussion of the results and possible areas for
further study.
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2 MOTIVATING DATA
The Second Randomized Intervention Treatment of Angina (RITA-2) trial (Henderson
et al., 1997, 2003) randomized 1018 eligible coronary artery disease patients from the United
Kingdom and Ireland to receive either Percutaneous Transluminal Coronary Angioplasty (PTCA,
n = 504) or continued medical treatment (n = 514). Those patients randomized to angioplasty
received the intervention in the first 3 months. The primary endpoint of the study was a com-
posite of all cause mortality and definite nonfatal myocardial infarction. After 7 years, there were
73 deaths (14.5%) on the PTCA arm and 63 (12%) on the medical arm (difference in proportions
+2.2%, 95% confidence interval [−2%, 6.4%], p = .21).
The study concluded that an initial policy of PTCA was associated with greater improve-
ment in angina symptoms, with this effect being particularly present in patients with more severe
angina, and that the increased risk of performing PTCA should be offset against these benefits.
RITA-2 was a pragmatic trial, so that although patients were initially randomized to PTCA
or medical treatment, in the course of the follow-up patients received further procedures accord-
ing to clinical need, and the trial was designed to compare a policy of beginning with medical
treatment against a policy of beginning with PTCA. Subsequent nonrandom interventions (NRIs)
were either PTCA, or when necessary, a coronary artery bypass graft (CABG). In the PTCA arm,
17.0% of patients had a second PTCA, while 12.7% had a CABG. By contrast, in the medical arm
27% went on to have a PTCA and 12.3% had a CABG.
The primary published analysis of our illustrative example, was an “Intention To Treat” anal-
ysis, that is, targeted a “treatment policy” estimand, with a composite outcome of time to first of
death or nonfatal myocardial infarction. Consistent with this ITT approach, this analysis did not
take account of nonrandomized interventions (of which, as we detail below, there were quite a
number, especially in the medical therapy arm, where many patients “crossed-over” to PTCA).
This suggested that our approach could be illustrated as follows: we artificially censor patients in
the medical arm at the time of their first non-randomized intervention, typically PTCA. Our first
analysis of the data with this artificial censoring uses within-arm imputation and therefore tar-
gets a per-protocol (i.e., hypothetical) estimand (in the language of EMA ICH E9 (R1) addendum).
However, in our sensitivity analysis we impute event times for these artificially censored patients,
but now using our method to assume that at these nonrandomized intervention times patients in
the medical arm “jumped” to the hazard in the PTCA arm. As this is effectively what happened
(because the typical nonrandomized intervention for medical arm patients was PTCA), this sen-
sitivity analysis is targeting the treatment policy estimand. We did this to provide an empirical
evaluation of the utility of our approach. This is because if our method works as intended, our
sensitivity analysis is targeting the ITT estimand, and we expect it to give similar results to the orig-
inal ITT analysis. Should our approach give clinically sensible results when we can cross-check it
with actual data, we will have more confidence in applying it in typical applications, where such
cross-checking is not possible.
In the next section we define information anchored sensitivity analysis.
3 INFORMATION ANCHORED SENSITIVITY ANALYSIS
If we consider a two-arm clinical trial such as the RITA-2 trial, the aim of a sensitivity analysis
is to assess the behavior of the treatment estimate under alternative, clinically plausible, CNAR
scenarios for post-censoring data. Since in RITA-2 post-censored patients in both treatment arms
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underwent PTCA, we propose using RBMI to model the post-censoring behavior based on the
PTCA arm; patients “jump” from the medical arm to the PTCA arm. Therefore, we estimate the
event time distribution of the PTCA arm in the usual manner, and use this to impute potential
post-censoring behavior on the medical arm.
However, variance estimators for the primary analysis may behave in an unexpected man-
ner under certain sensitivity analysis scenarios. Indeed, there are examples in which the usual
variance estimator with a reference-based method decreases as the proportion of missing values
increases (refer to Appendix A of Data S1). Such counter-intuitive properties would undermine
our confidence in the approach and of course would reward trialists for losing data!
Therefore, to justify the use of RBMI it is important to assess this is not the case by quan-
tifying the amount of statistical information available in the sensitivity analysis relative to the
primary analysis. This will establish whether the sensitivity analysis is injecting new information,
or taking away information, relative to the primary analysis. Cro et al. proposed the princi-
ple of information anchoring to address this, which we now formally define in the context of
time-to-data.
Consider a clinical trial in which time-to-event data is collected from patients, denoted by Y ,
in order to estimate a treatment effect 𝜃. We denote the data from those patients experiencing the
event by Yobs, and the data of those censored by Ycens. We make a primary set of assumptions, for
example, that all censored patients are “censored at random” (CAR). The estimate of 𝜃 under this
primary assumption is denoted by 𝜃obs,CAR, which, for a valid estimate under CAR, is calculated
using both the observed event and censoring times.
Furthermore, let us assume that we are able to observe a realization of the actual event times
for the censored patients, Ycens−realized,CAR, under the primary assumption of CAR. Of course, this
is a hypothetical construct, but it will help to frame the definition of information anchoring.
Taken together, the observed data, Yobs, and the realization of the event times for the censored
patients, Ycens−realized,CAR, we obtain a full data set under the primary CAR assumption. We define
𝜃full,primary to be the corresponding estimate of 𝜃 after fitting the primary analysis model to this full
dataset.
For the sensitivity analysis, we make a different set of assumptions concerning the distribution
of post-censoring data, that is, scenarios in which censoring is assumed to be informative (i.e.,
censored notat random).
Defined in the same manner as for the primary analysis, for the sensitivity analysis we
have 𝜃obs,sensitivity and ?̂?full,sensitivity, whereby “full” is defined analogously, assuming we are
able to observe the posited post-censoring behavior from our hypothetical construct denoted
Ycens−realized,sens, associated with a specific set of assumptions for the sensitivity analysis (e.g.,
“jump to PTCA arm”).
Furthermore, we define the observed information about 𝜃 under the primary and sensitivity
analyses by I(… ). Since there is less information when there is censored data, then we would
expect the ratio I(?̂?full,primary)
I(?̂?obs,primary)
> 1 and I(?̂?full,sensitivity)
I(?̂?obs,sensitivity)
> 1.







so that the proportion of information lost due to missing data is constant across primary and
sensitivity analyses. If Equation (1) above holds then we say that the sensitivity analysis is
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information anchored with regards to the primary analysis Cro et al. (2019). In the next section, we
show that for a two-arm clinical trial, and assuming a Tobit imputation model, RBMI for a time
to event outcome is information anchored. We do this by estimating each of the components of
Equation (1) above. We begin by defining the clinical trial setting and distributional assumptions,
then provide variance estimates assuming fully observed behavior, before moving on to estimate
the components under CAR, and finally provide the results for the specific informative censoring
scenario of interest (“jump to reference”).
4 INFORMATION ANCHORED SENSITIVITY ANALYSIS
FOR TIME-TO-EVENT DATA
4.1 Clinical trial setting with time-to-event data
We consider a two-arm clinical trial in which patients are randomized either to a reference or
active treatment arm. For example, the reference arm could be a placebo or standard of care
treatment.
We assume the times from patient randomization to when an event occurs, typically death or
treatment failure, are log normally distributed. For the primary endpoint we wish to estimate the
difference in the log normal survival times between the reference and active treatment arms.
In addition, we also measure a baseline covariate per patient at the time of randomization. Fur-
thermore, we assume that, due to randomization, the mean and variance of the baseline covariate
is the same in both arms.
Patients are right censored if they deviate from the study protocol, or do not experience the
event before the end of the study period. In addition, and without loss of generality, for ease
of exposition we assume that patients are only censored on the intervention arm, and therefore
those on the reference arm always experience the outcome event of interest (i.e., patients are fully
observed). We assume the baseline covariate is fully observed on both arms, and further, that the
log event times and baseline covariate are bivariate normally distributed.
As noted above, the treatment effect of interest is the difference in mean log time-to-event
between the trial arms, and we will test if this difference is statistically significant at the 5% level
using a standard t-test with shared sample variance estimate.
Throughout, we assume a single baseline covariate, but the approach generalizes to multi-
variable scenarios. Also note that we assume 1:1 randomization between the trial arms, so in the
expectation there are equal numbers of patients in the reference and active treatment arms.
Denoting subscript r for patients on the reference arm, we therefore have baseline covariate















, j = 1, … ,nr,
where r denotes the reference arm, and the baseline mean 𝜇1 is common between the reference
and active arms.
Using the subscript a for the active treatment arm, we now differentiate between two sets of
patients, those whose event times are observed (), and those whose event times are censored
(, for deviating from protocol). Throughout, we assume that nd of the na patients on the active
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treatment arm are censored at some fixed time point 𝜏, and the remaining no are followed until
they have the event, so that no + nd = na. The choice of a common censoring time 𝜏 allows the
use of standard results for the truncated normal distribution in the derived expressions.




























, j ∈ ,
For the primary analysis we assume censoring is at random, so that 𝜇d2 = 𝜇a2. For the sensi-
tivity analysis, we make the assumption of “Jump to Reference” (J2R ) for those censored on the
active arm.
We estimate the parameters of the unobserved data distribution from the reference arm,
and use this to impute event times for censored patients on the active treatment arm, so that,
post-censoring, these patients “jump to reference” (for details refer to Atkinson et al., 2019). An
example of this post-censoring behavior is the “jump to PTCA” sensitivity analysis scenario noted
above in the context of the RITA-2 trial. More formally, defining S(t) to be the usual survival func-
tion, and assuming a patient is censored on the active arm at a time point Ti, in such a “jump
to reference” scenario from this point on we use the survival function on the reference arm to
impute an event time. So that,
Spost,i(t|t > Ti, active) ∶= S(t|t > Ti, reference),
where the subscript post denotes the post-censoring distribution. This expression is the basis for
the multiple imputation process for the sensitivity analysis.
Since we are using a reference-based sensitivity analysis method, post imputation we
retain the primary analysis method, the t-test, for the difference in the log normal sur-
vival times, and apply this to each of the multiply imputed datasets created under the J2R
assumption for post-censoring behavior, and combine the estimates in the usual way with Rubin’s
rules.
Now, to confirm that the principle of information anchored sensitivity analyses holds for this







so that the proportion of information lost due to missing data is constant across primary and
sensitivity analyses.
We build this result step by step, evaluating each of the components in the above equation in
turn. We begin with the left-hand side of Equation (2), derive the information ratio I(?̂?full,CAR)
I(?̂?obs,CAR)
. In
the next subsection, we derive the upper part of this expression, when the data is fully observed
for the primary analysis, I(?̂?full,CAR). In Section 4.3, we estimate the variance following multiple
imputation under CAR, I(?̂?obs,CAR). Putting these two components together, we derive an expres-
sion for the left-hand side of the Equation (2) in Section 4.4 . The right-hand side of the equation is
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then derived for the J2R sensitivity analysis scenario in Section 4.5, I(?̂?full,J2R)
I(?̂?obs,J2R)
. Finally, we compare
the two ratios in Section 4.6.
4.2 Estimation of V(?̂?full,CAR)
On the active treatment arm, let us assume that we are able to observe a realization of the censored
log event times under the primary assumption of CAR, Ycens−realized,CAR, and we then combine this
with the fully observed data, Yobs, forming a full dataset under CAR. Fitting the primary analysis
model to this dataset leads to a treatment estimate ?̂?full,CAR, the subscript making the CAR setting
explicit. We start by deriving the expression for V(?̂?full,CAR), the variance of this estimate.
Conditioning on nd, the number of patients censored, the expected treatment effect is a
weighted average of the mean time to censoring, and the mean time to event for those fully


































Now, we additionally assume equal numbers of patients in both arms of the study nr = na = n,
and equal variance in both arms, so that 𝜎r22 = 𝜎a22 = 𝜎22. The expected value of this expres-




This establishes the expression for the top part of the left-hand side of Equation (2). In the
next section, we calculate the post multiple imputation estimate for Rubin’s variance under
CAR.
4.3 Rubin’s variance estimate following imputation under CAR
4.3.1 Tobit imputation model
To establish the properties of multiply imputed data on the active treatment arm, consistent with
our underlying normal model, we use a Tobit model fitted to the observed data as the imputation
model (Greene, 2003; Tobin, 1958). Based on estimates from this fitted model, we impute events
for the censored patients, and finally derive the variance of the combined sets of observed and
imputed data using Rubin’s rules.
We now calculate the estimate of the variance under the CAR assumption following multiple
imputation of the truncated (censored) data from the fitted Tobit model. We assume the estimates
𝛽 from the fitted imputation model are normally distributed.
Although MI is formally Bayesian, we assume the observed data dominates the posterior dis-
tribution, and, using inferential arguments set out on pp. 56–60 of Carpenter and Kenward (2013),
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we can, without any important loss of generality, assume the variance of the data is known in the
imputation model.
Accordingly, the multiple imputation process is as follows:
1. Fit the Tobit model to the observed data on the active arm regressing the log normal survival
times Yaj2 on the baseline covariate Yaj1, including the appropriate likelihood terms for those
censored at time 𝜏:
Yaj2 = 𝛽0 + Yaj1𝛽1 + 𝜀i, 𝜀i ∼  (0, ?̂?2.1), i = 1, … ,na,
resulting in the maximum likelihood estimates 𝛽0, 𝛽1, and estimate of the residual variance
?̂?2.1.






where X ∼ 𝜒2no−2. We assume the model estimates are bivariate normally distributed with mean
















we then take a draw from MVN(?̂?, V̂), resulting in a vector of estimates (𝛽0, 𝛽1).
3. Impute the censored observations using the resulting regression model with one set of the
estimates (𝛽0, 𝛽1), repeating this process until the imputed event time is greater than 𝜏:
Ỹ aj2 = 𝛽0 + 𝛽1Ỹ aj1 + ?̃?i, ?̃?i ∼  (0, ?̃?2.1), k = 1, … ,nd,
resulting in a complete dataset with no censored observations.
4. Repeat the above steps K times, resulting in K complete data sets.
5. Perform the substantive analysis, in this case the t-test, on each of the k = 1, … ,K complete
datasets in turn, resulting in estimates ?̂?k, ?̂?2k, which we combine to form overall estimates
using Rubin’s rules in the usual manner.
The MI estimate of 𝜃 is ?̂?MI,CAR = 1K
∑K
k=1?̂?k, for k = 1, … K.
Rubin’s variance estimator is defined as:


















(?̂?k − ?̂?MI)2. (5)
This is the standard MI procedure we would follow for the primary analysis assuming CAR.
Now, to derive an estimate of Rubin’s variance analytically we have to take a slightly different
approach since there is no closed form solution to calculate the maximum likelihood estimators
for the Tobit model.
4.3.2 Estimation of V(?̂?MI,CAR)
We begin by briefly presenting existing results for truncated normal distributions which we will
subsequently use. Recall, nd patients on the active arm are censored at a randomly defined, but
fixed time point 𝜏. Then,
















for j = 1, … ,nd patients censored at 𝜏;𝜑 andΦ being the density and CDF of the standard normal
distribution, respectively. The fraction part (in large square brackets) of the expression above is















Note that the expression in equation (6) is just the “usual” expected value, with an additional term√
𝜎22𝜆, where 𝜆 is treated as a constant for specific values of 𝜇a2, 𝜎22, and 𝜏.
Analogously, we also define:
















using the standard expression for the variance of the truncated normal distribution, and
analogously:




























Without loss of generality, the truncation limit 𝜏 is assumed to be greater than the mean
throughout the analysis.
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We now derive the variance estimate under CAR. The direction we take is to write down an
expression for a “typical” multiply imputed event time, and then work from there to derive an
expression for Rubin’s variance estimate. To do this, we combine our knowledge of the observed
data, the properties of the bivariate normal distribution (see Appendix B of Data S1), and the
results for the truncated normal distribution stated above.
The imputation model for the jth of nd censored values, from the kth of K imputed datasets,
is defined as:





?̃?22,k?̃? + 𝜖j,k, j ∈ , k = 1, … ,K, (8)
where Ỹ a2o,k is the expected value of the observed survival times for the censored patients,
with
?̃?2.1,k|Yo, ?̂?2.1 ∼ ?̂?2.1(no − 2)
𝜒2no−2
,
where ?̂?2.1 is the estimate of the residual variance from the fitted Tobit model, or equivalently,




̄̃Y a2o,k|Yo, ?̃?2.1,k ∼  (Y a2o,n−1o ?̃?2.1,k),
𝛽k|Yo, ?̃?2.1,k ∼  (r∕q, q−1?̃?2.1,k),
where r =
∑no
i=1(Yaj1 − Y a1o)(Yaj2 − Y a2o) and q =
∑no
i=1(Yaj1 − Y a1o)
2; the coefficient 𝛽k of the




?̃?22,k | ?̂?22 ∼ √?̂?22(na − 2)
𝜒na−2
,
where ?̂?22 is the sampling variance of the log survival times on the active treatment arm. We note
at this point that we use the 𝜒2-distribution here as an estimate of the sampling variance of the
standard deviation of ?̂?22,
√
?̂?22; and finally,
?̃?j,k| ̄̃Y a2d,k, ?̃?22,k ∼ Tr (0, ?̃?a2d,k , a = (𝜏 − ̄̃Y a2d,k)),
with ?̃?a2d,k the expected value of the unobserved survival times for the censored patients. The
right-hand side of the above expression denotes the truncated normal distribution with mean 0
and variance ?̃?a2d,k, truncated on the left-hand side at (𝜏 − ̄̃Y a2d,k); we use this relocation so that
the mean of this expression is centered at zero, with the variance as we require, and we ensure
that multiply imputed events are greater than the original censoring time for patient j. To estimate
the variance for both the observed and multiply imputed data, we have to evaluate Equation (3)
in Section 4.2. Since there is no missingness on the reference arm, the first part of this expression
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For the second part of Equation (3) pertaining to the active treatment arm, we decompose
the summation into observed and censored parts, substituting our new expressions for Ỹ aj2,k and
Y a2,k (for the latter, refer to Appendix C of Data S1),











Now, to calculate the above expression following multiple imputation we need to consider
both the components of Rubin’s variance estimator, that is, the between and within imputation
variance estimates (refer to Equations (4) and (5)):
























where wk,𝜆 and wk,?̇? are normally distributed variables with mean 0, which encompass the variability
of the inverse mills ratio terms in equation (8).
To arrive at the pooled variance of the treatment difference under CAR following MI,































Proof. Refer to Appendices C and D. ▪
4.4 Estimation of V (?̂?MI,CAR)
V (?̂?full,CAR)
We now have the building blocks for the first result, concerning the information ratio I(?̂?full,primary)
I(?̂?obs,primary)
which, under the primary assumption of CAR, is rewritten as I(?̂?full,CAR)
I(?̂?obs,CAR)
. In Equation (3) of
Section 4.2 we defined an estimate of I(?̂?full,CAR) for the hypothetical case of no censoring. In
the previous section, the expression for E[V(?̂?MI,CAR)] was obtained, which is an estimate of




Lemma 1. The ratio of the information in the full data relative to that in the incomplete data fol-
lowing multiple imputation assuming CAR, using the asymptotic expressions for Rubin’s variance
estimator, as K tends to infinity, is bounded above by
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nd
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, which is the correlation between the baseline mea-
surements and the event times squared. C is the variance of the standard deviation of 𝜎22, a
𝜒2-distributed variable, so that C = 𝜎2
[





, with N = na (e.g., p. 171 of
Kenney & Keeping, 1951).
Proof. Refer to Appendix E of Data S1. ▪
For the principle of information anchoring to hold, the ratio assuming CAR shown above
should be, at least approximately, the same numerically as that for the sensitivity analysis
following multiple imputation under the Jump to Reference assumption for censored patients.
4.5 Estimation of V (?̂?MI,J2R)
V (?̂?full,J2R)
Under J2R, the nd-censored patients obtain multiply imputed event times based on the
reference-arm hazard. This has the effect of reducing the difference between the estimated event
times on the two arms, since we now have nd additional observations generated under the hazard
from the reference arm. We referred to this phenomenon in our introductory comments as the
“dilution” or “mixing” effect.
Lemma 2. The ratio of the information in the full data relative to the incomplete data under the











+ (1 − 𝜋d)𝜎a2o + 𝜋d𝜎a2d
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+ 𝜋d(1 − 𝜋d)VAR(wk,𝜆r2 ) + 2𝜋d(1 − 𝜋d)𝜆r2
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(1 − 𝜋d)𝜎a2o + 𝜋d𝜎a2d + 𝜋d(1 − 𝜋d)Δ2c
n
, (16)
where Δc = 𝜇a2d − 𝜇a2o, with the inverse mills ratio calculated assuming N(𝜇r2, 𝜎22).
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Proof. For the derivation of Equations (15) and (16) refer to Appendices F and G. The proof of
Lemma 2 we delay until we have stated the theorem in full. ▪
Now, E[V(?̂?MI,J2R)] in Equation (15) is a rather complicated expression, but if we focus





or larger, it simplifies to an expression quite similar to that which
was derived for the CAR case. In fact, both expressions are dominated by the first term





, which was the first term of the analogous expression under the CAR assumption
(see Proposition 1).
Again, this makes sense because nd censored observations have been replaced with new event
times of a similar magnitude to those on the reference arm (in terms of the hazard). Therefore,
and in line with what might be expected, the variability in the difference between the event times
of both arms is somewhat reduced due the hazard dilution effect.
4.6 Information anchoring under Jump to Reference
Equations (15) and (16) provide the building blocks for the main result concerning information
anchoring.
Theorem 1. For bivariate log normally distributed right censored event times, the variance esti-
mate,E[V(?̂?MI,J2R)], is approximately information anchored.
Proof (outline). We hypothesize that despite using the J2R approach for sensitivity analysis, the
variance inflation due to missing data following MI is the same as that under CAR. We compare
the expression for the estimated variance under J2R in equation (15), E[V(?̂?MI,J2R)], with the pre-
dictedvariance under J2R, E[V̂anchored]. The latter we calculate using the other three terms in the










Therefore, using the expressions for the three terms on the right hand side, which we know from
earlier calculations, we can obtain the predicted information anchored variance,




Now, if we subtract the predicted term E[V̂anchored] above from the expression for the newly
derived expression for E[V̂(?̂?MI,J2R)] in Equation (15), we will obtain an estimate of the difference,
which, if information anchoring holds, should be rather small numerically.













+ 𝜋d(1 − 𝜋d)𝜆2r2 + 𝜋d(1 − 𝜋d)VAR(wk,𝜆r2) + 𝜋
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C ≈ 0.5 for large n. Workings are shown in Appendix H of Data S1.
This is an approximate bound on E[V(?̂?MI,J2R)] − E[Vanchored], and we now investigate the
approximate size of the difference in slightly more detail.
The upper bound on the difference in equation (18) is dominated in absolute magnitude by the
first two terms, and the negative ones in 𝜎a2o and Δ2c . Focussing only on these terms, we see that
the difference depends on the number of patients on each arm (n), the censoring level (𝜋d), the
variance of the data at time 2 (𝜎22), the variance of those observed (𝜎a2o), the correlation between
measurements at times 1 and 2 (𝜌2), the difference between the mean of those observed and those
deviating on the active arm at time 2 (Δc), and the inverse Mills ratio relating to the censoring
point 𝜏.
Using the same argument as Cro et al. (2016), we can apply standard trial size calculation
arguments to provide a realistic upper bound on Δc, assuming, for example, 80% power and 5%
significance:











which is of order O(𝜋d∕
√




which is of O(𝜋d∕n).
Since 𝜋d ≪ 0.5 can be expected for many sensitivity analyses, the whole expression is of the
order of approximately 10% of the total variance 𝜎22.
Therefore, we conclude that the upper bound on the difference is small in comparison to
the absolute information anchored variance, and the principles of information anchoring have
been approximately upheld following MI under J2R, confirming the proposition in Lemma 2 and
Theorem 1 above. ▪
Corollary 1. If the primary analysis model is a linear regression of the outcome, adjusted for
baseline, then Theorem 1 still holds.
Proof. The imputation model remains the same when the substantive model is a linear model
instead of the t-test. Following Cro et al. (2019), we replace the unconditional variance estimate
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This final result concludes the presentation of the theoretical results for information anchor-
ing for censored data. In the following sections, we validate these results using a simulation study,
and then illustrate their application using simulated data closely modeled on the RITA-2 trial
data. ▪
5 SIMULATION STUDY
We present the results of a simulation study which demonstrates the information anchoring
results derived in the previous section.
We began by assuming normally distributed baseline and time-to-event outcome data with-
out any censoring, and then increased the level of censoring on the active treatment arm. We
then compared the empirical results from multiply imputing events using the Tobit model (“sim-
ulation”), with those predicted using the theoretical results presented in the previous section
(“theory”).
The simulation study includes patients with a baseline measurement and event or censoring
times generated from a bivariate normal distribution with means and covariances as follows:
𝜇reference = [2, 1.9], 𝜇active = [2, 𝜇a2],






with a sample size n = nr = na = 250 in each arm. We imputed new event times for those cen-
sored at a fixed time point 𝜏 using the CAR and J2R MI methodology presented earlier with 50
imputed datasets (refer to Appendix I of Data S1 for example R code). We used mean baseline mea-
surements 𝜇r1 = 𝜇a1 = 2.0 on the reference and active treatment arms, respectively, and common
variance 𝜎11 = 0.4. There is no censoring on the reference arm with mean log normal survival
time of 𝜇r2 = 2.0, with 𝜇a2 unknown due to censoring on the active treatment arm. Again, in line
with our theoretical framework, the survival times have a known common variance 𝜎22 = 0.6.
Censoring was varied between 10% and 50% on the active treatment arm, with no censoring on
the reference arm. We simulated 500 datasets.
Table 1 presents the results. In the following, we have dropped the ?̂? from the expressions to
ease readability.
Column (A) shows the theoretical estimate of the information anchored variance following
MI under the assumption of J2R. In other words, we calculate each of the three elements on the






Column (B) shows the same theoretical estimate of Rubin’s variance under the J2R
assumption, E[V̂MI,J2R], but this time calculated using the expression for that term directly (i.e.,
the left-hand side of Equation (19) above), again using a priori values.
Column (C) uses the same calculation for information anchoring as defined in column (A)
(i.e., the right-hand side of Equation (19)), but estimates each of the quantities following MI of
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simulated data (denoted by the wide hat), not using the theoretical expressions derived earlier:




Column (D) is the analogue of Column B, but calculated using simulated data to estimate of
Rubin’s variance under the J2R assumption, denoted ̂E[VMI,J2R].
Columns (A) and (B) is the difference between the theoretically derived expressions
(E[V̂MI,J2R] − E[V̂anchored]), whereas columns (C) and (D) are the difference using simulated data
( ̂E[VMI,J2R] − ̂E[Vanchored]).
Following our theoretical expressions and assuming information anchoring holds, we would
expect Column A ≈ Column B and Column C ≈ Column D.
The results in Table 1 show excellent agreement when we compare the predicted differ-
ence using theoretically calculated values (column “Difference theory (A-B)”), with those from
simulated data (column “Difference simulation (C-D)).
The discrepancies between the true information anchored variance, and the MI estimate of it,
increase as the censoring level increases as we move down the table (column “Difference simula-
tion (C-D)”), from 0.00002 at 10% censoring to 0.0002 at 50% censoring, which are approximately
of the order of magnitude of the Monte Carlo simulation error (0.00016).
These results are in line with those for continuous longitudinal data presented in Cro
et al. (2019), which were also based on asymptotic arguments.
We conclude that the simulation results are consistent with our expectations and our infor-
mation anchoring arguments hold.
In the next section, we investigate whether information anchoring principles hold in a clinical
trial setting, inspired by data from the RITA-2 trial.
6 ILLUSTRATIVE EXAMPLE BASED ON THE RITA-2
TRIAL
Here, we use a simulated dataset very closely modeled on that from the RITA-2 trial. Our the-
oretically derived expressions assume a common right censoring threshold, 𝜏, for all patients.
However, for the RITA-2 data this assumption does not hold, and therefore, instead of using the
original data set directly, we have simulated data based on the descriptive statistics of the original
data, and chosen 𝜏 to reproduce the level of censoring of the original data.
We generated bivariate normally distributed data according to the properties RITA-2 trial
data, and chose 𝜏 to result in a censoring level of 27% on the medical arm, again as in the
RITA-2 data. The baseline mean we define to be the same on both arms (𝜇medical = 𝜇PTCA =
0.94). The fully observed log normal survival times on the PTCA arm have mean 𝜇PTCA =
1.75. The “true” mean of the log time on the medical arm, 𝜇r2, is unknown because of the
censoring:
?̂?medical = [0.94, ?̂?r2], ?̂?PTCA = [0.94, 1.75],
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T A B L E 2 Top part of table: Mean and SD (in brackets) for the medical and percutaneous












(K = 50) [3]
Medical (reference) 504 𝜇a2o = 1.60 (0.34) 𝜇r2 = 1.81 (0.42) 𝜇r2 = 1.81 (0.42)
PTCA (active) 514 𝜇r2 =1.75 (0.47) 𝜇r2 = 1.75 (0.47) 𝜇r2 = 1.75 (0.46)
Difference in group means
(t-test)
1,018 −0.15 [−0.21, −0.10] 0.06 [0.001, 0.12] 0.06 [−0.004, 0.11]
p < .001 p = .05 p = .07
Rubin’s variance estimator
(calculated)
E[V̂MI,CAR] = 0.0042 - E[V̂MI,J2R] = 0.0043
Rubin’s variance estimator
(following MI)
̂E[VMI,CAR] = 0.0042 - ̂E[VMI,J2R] = 0.0041
Notes: Bottom part of table: Comparison of endpoint from the primary analysis assuming CAR [1], the intention to
treat analysis of the original trial [2] and the sensitivity analysis assuming “Jump to PTCA” [3].
that is, 𝜎a1 = 𝜎r1 = 𝜎11 = 0.15, 𝜎a2 = 𝜎r2 = 𝜎22 = 0.22, and 𝜎12 = −0.04. For the medical arm, we
also know the mean time of the observed events, 𝜇a2o = 1.60, with associated variability, 𝜎a2o =
0.11.
The end-point is the difference in mean log survival time for patients on the medical arm
(standard of care, the reference arm) and those receiving PTCA (the active treatment arm). Fur-
thermore, for the primary analysis we assume there is no censoring on the PTCA arm, and patients
are censored at their first NRI on the medical arm.
With this simulated dataset, and consistent with the original trial, we assume that medical
arm patients censored because of a nonrandomized intervention “Jump to the PTCA arm.” This
allows us to compare the observed results (from analyzing the trial data) with (i) multiply imputed
data and (ii) our theoretical results.
Table 2 summarizes the parameter estimates and SDs, along with the results from the primary
and sensitivity analyses.
Column [1] provides the descriptive statistics and treatment difference for the primary anal-
ysis assuming CAR. Column [2] summarizes the results of the original trial when patients
were followed up irrespective of nonrandom interventions (i.e., “intention to treat”). Col-
umn [3] presents the results when censored patients are multiply imputed under “Jump to
PTCA,” again calculated using both the theoretically derived results and following multiple
imputation.
Under the primary analysis assumption of CAR, there is a significant treatment difference
(−0.15 [−0.21, −0.10], p<.001 [column [1], row 3]), whereas the difference is only marginally sig-
nificant following MI using “Jump to PTCA arm” (0.06 [−0.004, 0.11], p= .07 [column [3], row 3]).
The results from intention to treat analysis were similar to those following multiple imputation
(0.06 [0.001, 0.12], p = .05 [column [2], row 3]).
Consistent with our theory and the simulation results, there is little practical difference
between the theoretically predicted estimates using our calculated quantities, and those following
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multiple imputation. Furthermore, the estimates of Rubin’s variance in the primary and sensitiv-
ity analysis are also very similar (final row of Table 2), which provides additional validation of our
theoretical results. Plugging these and the other relevant values back into the information anchor-
ing equation, indicated that the sensitivity analysis was approximately information anchored, as
expected.
7 DISCUSSION
Given the increasingly prominent role of sensitivity analysis in the analysis of clinical trials, exem-
plified by the ICH E9 addendum published in 2019 CHMP (2019), it is important to provide
methods which are not only easy to implement and use, but which are also clinically plausible
and contextually relevant to the trial team and other stakeholders. This also responds to the FDA
mandated report by the U.S. National Research Council in 2010, which highlighted the lack of
such sensitivity analysis methods NRC (2010). To address this, reference based multiple impu-
tation methods have recently been extended for time to event data (Atkinson, 2019; Atkinson
et al., 2019).
However, there has been considerable discussion and numerous publications concerning
the perceived conservativeness of Rubin’s variance estimator when the imputation and analysis
models are not congenial (Hughes et al., 2014; Kim, 2004; Nielson, 2003; Robins, Hernan, & Brum-
back, 2000), a situation which occurs with RBMI (Liu and Peng (2016)). Following the arguments
set out in Cro et al. (2019), we believe it is important that sensitivity analyses are information
anchored, so that as we move to the sensitivity analysis we do not inflate the statistical informa-
tion about the treatment effect. As the theory and the simulations presented here show, this is
achieved when we use Rubin’s variance estimator. By contrast, in this setting, using the bootstrap
(e.g., Liu and Peng) means that the information about the treatment effect is being increased as
we move to the sensitivity analysis (so we are rewarded in effect for missing data). We argue the
conservativeness of Rubin’s variance estimator is of less concern compared to the requirement
to ensure that the sensitivity analysis does not (implicitly or explicitly) increase the statistical
information about the treatment effect. Therefore, we believe Rubin’s variance estimator is more
appropriate to use in sensitivity analyses of this type.
The information anchoring principle states that the statistical information should be held con-
stant across the primary and sensitivity analyses, and that it should certainly not be increased,
because (Cro et al. (2019)) “an information positive sensitivity analysis is rarely justifiable,
implying … that the more data are missing, the more certain we are about the treatment
effect under the sensitivity analysis,” and, “while information negative sensitivity analyses
provides an incentive for minimizing the missing data, there is no natural consensus about
the appropriate loss of information.” We showed that if we wish to follow the information
anchoring principle, reference-based sensitivity analysis implemented using multiple imputa-
tion is statistically appropriate for inference trials with censored outcome data that can be
modelled with the truncated normal distribution. A natural example of this is time-to-event
data, where the survival times follow a log-normal distribution. We built our theoretical results
based on using Tobit regression as imputation model, and showed that, assuming log nor-
mal survival times and right censored data, information anchoring holds. We validated these
results by simulation, with the results closely mirroring those obtained in the continuous lon-
gitudinal setting. As a reviewer pointed out, whilst we assumed no difference in the baseline
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covariate between the two arms, the framework would allow an adjusted analysis of variance
analysis.
A limitation of the approach is that we assume a fixed censoring point 𝜏, primarily to enable us
to use standard results for the theoretical work. Having a fixed censoring point is unusual in indi-
vidual patient randomized trials, but can occur in cluster randomized trials where interventions
start on a specific day, and is most often the case, by design, for emulated trials using observational
data (Atkinson et al. (2020)). Notwithstanding these examples, most clinical trials have rolling
recruitment and stop at a fixed calendar time, which means that the censoring time is variable.
Therefore, as proposed by a reviewer, we performed additional simulations with random censor-
ing, and compared the results with those from the theory based on a fixed censoring point (refer
to Supplementary Material Appendix J of Data S1). The results suggest that, at least empirically,
our theory also holds with random censoring, although this remains to be formally confirmed.
A further potential limitation of the approach presented here is using the t-test, or anal-
ysis of covariance, to determine the mean log difference in the event times. The most com-
mon choice for the primary analysis model would be the Cox Proportional Hazards (CPH)
model, with the hazard ratio over the total follow-up period defined as treatment effect for the
trial. However, it is important to recognize that the CPH model inherently assumes that the
hazards are proportional, even though this is increasingly being challenged in many clinical
settings (Royston & Parmar, 2011, 2013). The restricted mean survival time (RMST) is now fre-
quently used instead of the hazard ratio as a preferable clinical endpoint. Although not always
equivalent to the RMST, there are clear parallels between using the RMST and the mean log
time to event used to calculate the endpoint in our theoretical framework. Nevertheless, an
extension of the information anchoring theory to the proportional hazards setting would be
beneficial.
We have focused solely on the “Jump to Reference” assumption (from one of a number of
proposals suggested in Carpenter et al., 2013), since this was the approach which, following map-
ping to the time to event setting, had a clear clinical context when assuming proportional hazards
(refer to Atkinson et al. (2019)).
In addition, our simulation results and those from a previous study (cf, figure 3 of Atkin-
son et al., 2019) indicate that information anchoring holds for censoring levels of approximately
50% or less. We believe this is sufficient reassurance for practical use since we are not primarily
intending this approach to be applied to administrative censoring (which we know is completely
at random and may reach high proportions), but to censoring (for various reasons, typically
treatment changes) in the course of the follow-up.
The information anchoring approximation is most accurate when randomization is 1:1. When
this is not the case, the theory presented here suggests how to modify the procedure to retain
information anchoring. For simplicity the theory presented here focuses on the case in which
there is censoring in one arm. The approach could be extended for deviations in both arms in an
analogous manner to that set out by Cro et al.
Approaches varying an explicitly defined sensitivity parameter, such as 𝛿-methods, are often
presented as an alternative to RBMI for performing sensitivity analysis. Such methods intro-
duce a 𝛿-size change to each patient’s hazard at the censoring time point, which is varied to
reflect an improvement or a deterioration in their post-censoring condition (Lipkovich, Ratitch,
& O’Kelly, 2016; Lu, Li, & Koch, 2015). While attractive due to their simplicity, determining a
meaningful range of values for 𝛿 has often proved to be a practical drawback. The process often
requires iterative discussions within the trial team, and these can become difficult to conclude
satisfactorily, especially when considering delta multipliers of a hazard or odds ratio, and how
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this may vary by treatment arm. Nevertheless, Cro et al. showed that the information anchoring
principle holds for specific settings with delta methods, but this has yet to be demonstrated for
time to event data. This is certainly an area for potential further study.
In summary, the attraction of RBMI sensitivity analysis methods is that they are acces-
sible, that is, they are both simple to understand and straightforward to implement. Taking
such an approach avoids the alternative in which we would have to explicitly model the
event and censoring process, which is often rather complex to achieve in practice, even for
experts in the field. We have demonstrated that RBMI in the time to event setting, albeit
under specific distributional assumptions, is information anchored, providing both regulators
and industry with confidence for using this approach for sensitivity analysis for time to event
data.
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